Canopy Growth Q4 Revenue Up 10%, International Cannabis Jumps 68%; Gross Margins Fall Amid Restatement
CGC is trading near its 52-week low of $0.844 (14% above the low).
Summary
Canopy Growth reported Q4 FY226 results with consolidated net revenue up 10% to $71.2M, driven by strong growth in Canada Medical (27%) and International Cannabis (68%) segments. However, consolidated gross margin declined to 12% in Q4, impacted by $10.7M in inventory charges, though adjusted gross margin improved to 27%. This earnings report follows the company's recent restatement of financial statements and the filing of a restated 10-K today, which revealed material weaknesses in internal controls. The mixed performance, with strong segment revenue growth but overall margin pressure, provides the first clear financial picture after significant accounting issues. The company ended the year with $131.3M in net cash and aims for positive Adjusted EBITDA in FY2027, which will be a key metric to watch.
At the time of this announcement, CGC was trading at $0.97 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $452.1M. The 52-week trading range was $0.84 to $2.38. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.